Interleukin-6 modulates production of T lymphocyte–derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis
Version of Record online: 29 DEC 2005
Copyright © 2006 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 54, Issue 1, pages 158–168, January 2006
How to Cite
Wong, P. K. K., Quinn, J. M. W., Sims, N. A., van Nieuwenhuijze, A., Campbell, I. K. and Wicks, I. P. (2006), Interleukin-6 modulates production of T lymphocyte–derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis & Rheumatism, 54: 158–168. doi: 10.1002/art.21537
- Issue online: 29 DEC 2005
- Version of Record online: 29 DEC 2005
- Manuscript Accepted: 29 SEP 2005
- Manuscript Received: 7 APR 2005
- Reid Charitable Trusts
- Arthritis Foundation of Australia
- National Health and Medical Research Council of Australia
To determine the cellular mediators of antigen-induced arthritis (AIA) and the relative contribution of members of the interleukin-6 (IL-6) family and tumor necrosis factor (TNF) in AIA.
AIA was induced in mice deficient in T and B lymphocytes, IL-6 (IL-6−/−), TNF (TNF−/−), IL-11 receptor, and oncostatin M receptor, by immunization with methylated bovine serum albumin (mBSA) followed 7 days later by intraarticular injection of mBSA. Arthritis severity was assessed histologically, and T lymphocyte responses were assessed in vitro. Anti-TNF neutralizing antibody was administered to wild-type mice during AIA. Bone marrow osteoclasts were generated in vitro via culture with RANKL and macrophage colony-stimulating factor.
AIA was dependent on CD4+ T lymphocytes, but not CD8+ T lymphocytes or B cells. IL-6−/− mice had reduced AIA severity and fewer osteoclasts at sites of bone erosion. This protective effect was not seen with a deficiency of other IL-6 family members and was similar to that in TNF−/− mice or wild-type mice receiving TNF blockade treatment. IL-6−/− CD4+ T lymphocytes from draining lymph nodes had reduced antigen-induced proliferation and produced less IL-17 and less RANKL, relative to osteoprotegerin, than cells from wild-type mice. Bone marrow from IL-6−/− mice generated fewer osteoclasts in vitro than bone marrow from either wild-type or TNF−/− mice.
AIA is driven by CD4+ T lymphocytes. IL-6 is an important mediator of bone destruction in AIA because it regulates T lymphocyte production of key osteoclastogenic cytokines and inflammation-induced bone marrow osteoclast differentiation. These findings have implications for reducing bone and joint damage in rheumatoid arthritis.